These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27241239)

  • 61. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Lin CS; Krishnan AV; Park SB; Kiernan MC
    Arch Neurol; 2011 Jul; 68(7):862-9. PubMed ID: 21747028
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins.
    Lawley A; Seri S; Rajabally YA
    Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CIDP prognosis in patients with IVIG treatment-related fluctuations.
    Cook M; Pasnoor M; Ajroud-Driss S; Brannagan TH; Dimachkie MM; Allen JA
    Muscle Nerve; 2023 Jan; 67(1):69-73. PubMed ID: 36330716
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
    Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
    J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP.
    Iijima M; Yamamoto M; Hirayama M; Tanaka F; Katsuno M; Mori K; Koike H; Hattori N; Arimura K; Nakagawa M; Yoshikawa H; Hayasaka K; Onodera O; Baba M; Yasuda H; Saito T; Nakazato M; Nakashima K; Kira J; Kaji R; Oka N; Sobue G
    Neurology; 2005 Apr; 64(8):1471-5. PubMed ID: 15851750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immune Globulin Subcutaneous (Human) 20% (Hizentra
    Lamb YN; Syed YY; Dhillon S
    CNS Drugs; 2019 Aug; 33(8):831-838. PubMed ID: 31347096
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Teramoto H; Morita A; Hara M; Ninomiya S; Shigihara S; Kusunoki S; Kamei S
    Intern Med; 2015; 54(14):1791-3. PubMed ID: 26179538
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
    Press R; Hiew FL; Rajabally YA
    Acta Neurol Scand; 2016 Apr; 133(4):228-38. PubMed ID: 26437234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy.
    Wong AH; Fukami Y; Sudo M; Kokubun N; Hamada S; Yuki N
    J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):275-9. PubMed ID: 25814494
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Measuring disease activity and clinical response during maintenance therapy in CIDP: from ICE trial outcome measures to future clinical biomarkers.
    Katzberg HD; Latov N; Walker FO
    Neurodegener Dis Manag; 2017 Apr; 7(2):147-156. PubMed ID: 28112008
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.
    Bright RJ; Wilkinson J; Coventry BJ
    BMC Neurol; 2014 Feb; 14():26. PubMed ID: 24507546
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
    Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T
    J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Treatment of chronic inflammatory polyradiculoneuropathy].
    Nicolas G
    Rev Med Interne; 2008 Jun; 29 Spec No 2():1-8. PubMed ID: 18927988
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
    Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
    Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy.
    Rajabally YA; Blomkwist-Markens PH; Katzberg HD
    Neurodegener Dis Manag; 2015; 5(3):257-68. PubMed ID: 26107324
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical and long-term characteristics of the subtypes of chronic inflammatory demyelinating polyneuropathy].
    Shimizu F; Nemoto J; Takeshita Y; Maeda T; Koga M; Kanda T
    Rinsho Shinkeigaku; 2022 Mar; 62(3):173-177. PubMed ID: 35228460
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of chronic inflammatory demyelinating polyradiculopathy.
    Doneddu PE; Nobile-Orazio E
    Curr Opin Neurol; 2018 Oct; 31(5):511-516. PubMed ID: 30045075
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Therapeutic responsiveness in chronic inflammatory demyelinating polyradiculoneuropathy].
    Iijima M
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1012-4. PubMed ID: 22277461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.